DNTH - NASDAQ
Dianthus Therapeutics, Inc.
$84.13
+0.88%Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
At a Glance
Live Snapshotdnth
Total Stockholders' Equity
Last Annual Value
493.40M
3-Year CAGR
89%
5-Year CAGR
28%
10-Year CAGR
49%
Dianthus Therapeutics, Inc. Competitors Analysis of Total Stockholders' Equity
| Company | Total Stockholders' Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Dianthus Therapeutics, Inc. NASDAQ:DNTH | 493.40M | 43.0% | 23.4% | 49.2% | |
 BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | 411.10M | N/A | N/A | N/A | |
 AnaptysBio, Inc. NASDAQ:ANAB | 37.21M | -25.0% | -36.4% | -0.5% | |
 Nektar Therapeutics NASDAQ:NKTR | 89.83M | -11.8% | -33.3% | 0.2% | |
 Enliven Therapeutics, Inc. NASDAQ:ELVN | 459.60M | 23.2% | 33.9% | N/A | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 160.88M | -17.6% | -26.1% | N/A | |
 Tourmaline Bio, Inc. NASDAQ:TRML | 300.05M | 13.5% | 4.3% | N/A | |
 Taysha Gene Therapies, Inc. NASDAQ:TSHA | 246.94M | 48.8% | 21.0% | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 221.87M | -3.0% | -10.1% | N/A |
Dianthus Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your DNTH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.